CIK 0001650648 · Non-accelerated filer<br>Smaller reporting company
4D Molecular Therapeutics, Inc.
Sign in to watch- Ticker
- FDMT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 473506994
- Phone
- 5105052680
- Business address
- 5858 HORTON STREET #455, EMERYVILLE, CA, 94608
- Former names
- 4D Molecular Therapeutics Inc., 4D Molecular Therapeutics Inc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,724,648
- in 7 filings, $2.7M under 10b5-1 plans
Net −$2,724,648. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-09-23 | Kasahara Noriyuki Director | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2022-09-23 | Kamal Fariborz President & COO | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2022-09-01 | FISHMAN ROBERT S Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2022-09-01 | Moretti August J Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | −60,000 | 60,000 | ||
| 2022-09-01 | Kamal Fariborz See Remarks | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2022-09-01 | Bizily Scott Chief Legal and HR Officer | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2022-06-18 | Bizily Scott Chief Legal and HR Officer | Grant or award · Stock Option (Right to Buy) | +24,000 | 24,000 | ||
| 2022-05-23 | Tomasello Shawn Director | Grant or award · Stock Option (Right to Buy) | +22,500 | 22,500 | ||
| 2022-05-23 | THEUER CHARLES Director | Grant or award · Stock Option (Right to Buy) | +22,500 | 22,500 | ||
| 2022-05-23 | MILLIGAN JOHN F Director | Grant or award · Stock Option (Right to Buy) | +33,750 | 33,750 | ||
| 2022-05-23 | Miller-Rich Nancy Director | Grant or award · Stock Option (Right to Buy) | +22,500 | 22,500 | ||
| 2022-05-23 | GRAY SUSANNAH Director | Grant or award · Stock Option (Right to Buy) | +22,500 | 22,500 | ||
| 2022-05-23 | Chacko Jacob Director | Grant or award · Stock Option (Right to Buy) | +22,500 | 22,500 | ||
| 2022-02-01 | Moretti August J Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | −65,000 | 65,000 | ||
| 2022-02-01 | Zimmermann Carolyne Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2022-02-01 | Kirn David Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2022-02-01 | Kamal Fariborz See Remarks | Grant or award · Stock Option (Right to Buy) | +70,000 | 70,000 | ||
| 2022-02-01 | FISHMAN ROBERT S Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2021-10-22 | SCHAFFER DAVID Director | Sale | −1,900 | $31.00 | $59K | 901,215 |
| 2021-10-21 | SCHAFFER DAVID Director | Sale | −22,820 | $31.56 | $720K | 903,115 |
Page 14 of 16 · 319 trades